Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actavis Enters U.S. Generic Market Through $500 Mil. Amide Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Iceland-based Actavis will diversify its European-centric revenue base through the acquisition of Amide, located in New Jersey. An Amide manufacturing site currently under construction and slated for completion in 2006 could significantly boost U.S. capacity for the combined companies.

You may also be interested in...



Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.

Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.

Actavis' U.S. Portfolio To Get A Boost From Alpharma Generic Acquisition

The Iceland-based firm will become a top-five global generic player after acquiring Alpharma's generic business for $810 mil.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel